Biogen (BUE:BIIB) Cyclically Adjusted Book per Share: ARS10,958.44 (As of Mar. 2026)


BUE:BIIB Biogen Inc BUE:BIIB
64 GF Score
Price ARS24,000.00
GF Value ARS22,612.19
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted Book per Share?

Biogen BUE:BIIB -1.07% 64 Cyclically Adjusted Book per Share is ARS10,958.44 as of Mar. 2026. GuruFocus rates BUE:BIIB with a GF Score™ of 64/100 and a GF Value™ of ARS22,612.19 (Fairly Valued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biogen's adjusted book value per share for the three months ended in Mar. 2026 was ARS176,691.382. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ARS10,958.44 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biogen's average Cyclically Adjusted Book Growth Rate was 10.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 10.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 12.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 12.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Biogen was 60.90% per year. The lowest was 8.90% per year. And the median was 13.60% per year.

As of today (2026-07-11), Biogen's current stock price is ARS24000.00. Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ARS10,958.44. Biogen's Cyclically Adjusted PB Ratio of today is 2.19.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 9.94. The lowest was 1.31. And the median was 4.82.


Biogen  (BUE:BIIB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=24000.00/10958.44
=2.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 9.94. The lowest was 1.31. And the median was 4.82.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biogen Cyclically Adjusted Book per Share Related Terms


Biogen Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted Book per Share Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 947.50 1,808.36 5,777.02 7,676.56 11,004.61

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,878.55 8,405.29 10,896.42 11,004.61 10,958.44

BUE:BIIB vs OGN, AMRN, SCLX: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.


BUE:BIIB
64GF Score
Biogen Inc BUE:BIIB
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=176691.382/330.2130*330.2130
=176,691.382

Current CPI (Mar. 2026) = 330.2130.

Biogen Quarterly Data

Book Value per Share CPI Adj_Book
201606 727.553 241.018 996.803
201609 830.769 241.428 1,136.284
201612 890.977 241.432 1,218.613
201703 826.971 243.801 1,120.080
201706 903.443 244.955 1,217.892
201709 1,065.652 246.819 1,425.709
201712 1,138.730 246.524 1,525.302
201803 1,341.978 249.554 1,775.722
201806 1,517.982 251.989 1,989.203
201809 2,514.342 252.439 3,288.986
201812 2,493.195 251.233 3,276.980
201903 2,769.522 254.202 3,597.659
201906 3,131.616 256.143 4,037.199
201909 4,303.104 256.759 5,534.142
201912 4,578.479 256.974 5,883.371
202003 4,654.975 258.115 5,955.226
202006 4,890.673 257.797 6,264.479
202009 5,189.805 260.280 6,584.221
202012 5,713.848 260.474 7,243.667
202103 6,389.459 264.877 7,965.518
202106 6,831.170 271.696 8,302.445
202109 6,942.380 274.310 8,357.202
202112 7,485.763 278.802 8,866.135
202203 8,183.789 287.504 9,399.499
202206 9,838.967 296.311 10,964.678
202209 12,327.470 296.808 13,714.896
202212 15,598.319 296.797 17,354.514
202303 18,822.641 301.836 20,592.245
202306 23,978.287 305.109 25,951.191
202309 34,980.027 307.789 37,528.501
202312 36,870.831 306.746 39,691.561
202403 88,514.867 312.332 93,582.341
202406 98,332.335 314.175 103,352.002
202409 106,720.204 315.301 111,767.482
202412 115,861.076 315.605 121,223.788
202503 123,548.951 319.799 127,572.224
202506 142,808.120 322.561 146,195.906
202509 168,548.131 324.800 171,357.094
202512 180,514.606 324.054 183,945.483
202603 176,691.382 330.213 176,691.382

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ARS10,958.44 mean?
Biogen (BUE:BIIB) has a Cyclically Adjusted Book per Share of ARS10,958.44 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Biogen and its competitors.
Is Biogen's Cyclically Adjusted Book per Share too high?
Biogen's current Cyclically Adjusted Book per Share is ARS10,958.44. Overall, Biogen has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Cyclically Adjusted Book per Share compare to OGN and AMRN?
Biogen's Cyclically Adjusted Book per Share of ARS10,958.44 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Biogen and its competitors. Biogen's current Cyclically Adjusted Book per Share is ARS10,958.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (BUE:BIIB) is currently considered Fairly Valued. The stock's GF Value™ is ARS22,612.19, compared to a current price of ARS24,000.00 — trading 6.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is ARS10,958.44. Biogen's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Biogen (BUE:BIIB), the current Cyclically Adjusted Book per Share is ARS10,958.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (BUE:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of ARS24,000.00 is trading 6.1% above its estimated GF Value™ of ARS22,612.19. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for BUE:BIIB:

  • Cyclically Adjusted Book per Share: ARS10,958.44
  • GF Value™: ARS22,612.19 vs. price of ARS24,000.00 (6.1% above fair value)
  • GF Score™: 64/100 with 7 warning signs

No single metric tells the full story. See the BUE:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
64GF Score

Get the complete analysis for BUE:BIIB

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS24,000.00
Price
ARS22,612.19
GF Value